Raycash, a stablecoin payments startup spun out of Zama, has launched a private beta on Ethereum mainnet allowing users to hold encrypted dollar balances, send peer-to-peer payments, and earn yield. The app uses Fully Homomorphic Encryption to keep transaction amounts confidential while keeping sender and recipient addresses visible onchain. This approach balances privacy and transparency, aiming to prove demand for encrypted finance beyond protocol milestones. With an 80,000-person waitlist, the beta's success will depend on user adoption and system performance given the resource-intensive encryption technology.
Raycash's launch of confidential stablecoin payments on Ethereum provides context for readers interested in cryptocurrency trends. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 09, 2026 16:01 WIB: out of 50 major cryptocurrencies, 6 rose and 43 fell today. Balancer (BAL) gained 11.14% to Rp16.297, EOS.IO (EOS) rose 8.13% to Rp12.649, while Ripple (XRP) declined 5.56% to Rp19.874 with a Pluang order activity of 38% Sell and 62% Buy.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
